Solid first quarter leaves J&J investors nonplussed

16 April 2024
j-j_johnson_lobby_large

US healthcare giant Johnson & Johnson (NYSE: JNJ) has announced its financial results for the first quarter of 2024.

The conglomerate posted $21.38 billion in total sales, up more than 2% from the same quarter in 2023 and marginally below the $21.4 billion expected by Wall Street analysts, based on a survey of analysts by LSEG.

"Reflects our sharpened focus and the progress in our portfolio and pipeline"Excluding certain items, adjusted earnings per share were $2.71, a 12% rise on a year ago and ahead of the $2.64 anticipated by analysts.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical